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A B S T R A C T
Objective: We evaluated the prognostic impact of quantitative assessment by maximum standardized uptake
value (SUVmax), metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG) on [F-18] FDG PET/CT
for patients with peritoneal carcinomatosis from epithelial ovarian cancer (EOC).
Methods: Thirty-one patients with EOC underwent PET/CT for an early restaging after cytoreductive surgery,
having been diagnosed with carcinomatosis (before chemotherapy). The SUVmax, MTV (cm3; 42% threshold)
and TLG (g) were registered on residual peritoneal lesions. The patients were followed up 20 ± 12 months
thereafter. The PET/CT results were compared to overall survival (OS).
Results: The Kaplan-Meier survival analysis for the SUVmax did not reveal signiﬁcant diﬀerences in OS
(p = 0.48). The MTV survival analysis showed a signiﬁcant higher OS in patients presenting with a higher
tumour burden than those with less tumour burden (p = 0.01; 26 vs. 14 months), whereas TLG exhibited a
similar trend though not signiﬁcant (p = 0.06). Apart from chemo-resistance, the higher the MTV, the better will
be the response to chemotherapy.
Conclusions: Quantitative assessment by MTV rather than by SUVmax and TLG on PET/CT may be helpful for
stratifying patients who present with peritoneal carcinomatosis from EOC, in order to implement the appropriate
therapeutic regimen.
1. Introduction
Epithelial ovarian cancer (EOC) is the most fatal gynaecological
malignancy. Almost 22,000 cases are being diagnosed in the United
States annually, and 14,240 estimated deaths are expected in 2016. [1].
The number of cases is similar in other developed countries, with an
age-standardised rate per 100,000 women of 9.1 [2]. This disease is
frequently diagnosed at advanced stages, because EOC spreads in-
traperitoneally through seeding, via direct invasion or via the lym-
phatic or vascular circulation [3]. This stage, called peritoneal carci-
nomatosis, represents a clinical challenge.
Although primary cytoreductive surgery (CRS) followed by taxane/
platinum-based chemotherapy (CHTx) is considered the standard
approach [4], unfortunately patients have a high death rate following
this ineﬀective and somewhat life-threatening therapy. Several authors
have suggested that maximal cytoreduction after surgery is one of the
most powerful prognostic factors [5–7]. Nevertheless, the presence of
residual large-volume disease after surgery does not preclude beneﬁts
from subsequent treatments.
The prognostic impact of the residual (loco-regional/peritoneal)
tumour burden assessed by positron emission tomography/computed
tomography (PET/CT) has not yet been completely investigated. In fact,
the appraisal of the peritoneal involvement is usually performed by
contrast-enhanced CT and magnetic resonance imaging, but sensitivity
is reduced because the anatomical imaging considers only size criteria
and does not distinguish the functional alterations that may occur
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within the tumour tissue.
Recently, the PET/CT has exhibited valuable diagnostic accuracy for
identifying primary tumours, regional lymph nodes, distant metastases
and signiﬁcant peritoneal involvement resulting from EOC [8–10].
Moreover, some studies have shown that PET/CT is useful for mon-
itoring response to treatment [11], both surgical and chemo-ther-
apeutic, and for detecting residual disease during and/or after the
completion of therapy [12,13].
Data that describe the role of PET/CT quantitative parameters for
the prediction of outcome are limited. Metabolic tumour volume (MTV)
and total lesion glycolysis (TLG) are measures of the metabolic activity
of tumours derived from ﬂuorine-18 ﬂuorodeoxyglucose ([18F] FDG)
uptake on PET/CT images. The purpose of this study was to investigate
the relationship between the functional tumour parameters (SUVmax,
MTV and TLG) and the clinical outcome in EOC patients who demon-
strated residual peritoneal involvement after CRS and for whom ad-
juvant chemotherapy was planned.
2. Material and methods
We retrospectively reviewed the Institute tumour registry for pa-
tients who had an EOC histological diagnosis between January 2008
and August 2011. Among them, patients presenting with peritoneal
carcinomatosis at CRS, as per II/III stage according to the International
Federation of Gynaecology and Obstetrics (FIGO), were enrolled
(Table 1). The patients were required to have undergone an [18F] FDG
PET/CT study between the established diagnosis, at the time of surgery,
and before any further scheduled chemotherapy (within
4 ± 1 months) with the intent of restaging, and to have received at
least 8 months' follow-up. All subjects received CRS and no less than a
complete pelvic excision (i.e. partial debulking). Additional inclusion
criteria were age at entry of 18 years or older, a negative pregnancy test
and Gynaecologic Oncology Group (GOG) Performance Status of 0, 1, 2
or 3.
The patients who had received neo-adjuvant therapy or re-inter-
vention, or were classiﬁed as stage IV, were excluded.
The histological specimen, grade, haematological parameters and
Ca-125 serum levels, and the site of peritoneal involvement as well as
the treatment adopted thereafter were retrieved from each patient’s
medical record. The surgical staging was assigned according to the
FIGO stage. The timing of the scheduled chemotherapy was im-
plemented in compliance with each patient's GOG state post-surgery
and according to the referring physicians (Table 2).
The ethical committee of our Institute approved the protocol. All
patients who underwent the study signed an informed consent form in
accordance with the Declaration of Helsinki.
The patients underwent [18F] FDG PET/CT. Patients were well-
hydrated before receiving [18F]FDG intravenously (370–555 MBq).
Sixty minutes after the tracer injection, PET and CT were carried out
with a commercial PET/CT scanner (GE Discovery VCT scanner;
Waukesha, WI) that combined a PET scanner and a Light Speed VCT 64
row MDCT system. MDCT (pitchx 1.5; 120 mAs; 120 kVp) was per-
formed without the use of intravenous and/or oral contrast mediums.
The PET scanning was subsequently performed, acquiring 3 min per
bed position and six to eight beds per patient, depending on patients'
heights. The raw CT data were reconstructed into transverse images
with a 3.75-mm section thickness. Sagittal and coronal CT images were
generated by reconstruction of the transverse data. Raw PET data were
reconstructed with and without attenuation correction into transverse,
sagittal and coronal images. Attenuation correction was based on CT
attenuation coeﬃcients, which were determined by iterative re-
construction. Patients fasted 4–6 h prior to imaging. Blood glucose le-
vels were determined in all patients before [18F]FDG administration,
and a cut-oﬀ value of less than 8.04 mmol/L (145 mg/dL) was con-
sidered appropriate for performing the examination.
All images were reviewed by using a PET/CT fusion software
(Volumetrix for PET-CT and Advantage Workstation, AW volume share
4.5; GE Healthcare, Waukesha, WI, USA). Each PET/CT study was in-
terpreted by two experienced nuclear medicine physicians (G.S., and
P.M., each with 15 years of expertise); one of them was also a radi-
ologist. They were blinded to the patient histories. The examiners ﬁrst
evaluated the CT images alone.
The mass size was visually estimated and measured for minimum
and maximum diameters by using a vendor-provided software
(Volumetrix for PET-CT; GE Healthcare, Waukesha, WI, USA). A lesion
(site) was deﬁned as an identiﬁable peritoneal mass (i.e. peritoneal coin
or omental/mesenteric fat thickening) or a pathological lymph node
with soft-tissue/abdominal window settings (i.e. n. 1 lymph nodes>
1 cm or n. 3 in cluster), within the pelvic/abdominal environment.
The PET studies were evaluated both visually and semi-quantita-
tively. A SUVmax cut-oﬀ value of 2.5 (established by a ROC curves
analysis) is considered to provide excellent speciﬁcity and sensitivity
for detecting lesions. Accordingly, an uptake higher than 2.5 was re-
ported as signiﬁcant. On the PET scan, the body-weight corrected
maximum standardized uptake (SUVmax) values as well as the MTV
(cm3; 42% threshold) and TLG (g) were determined using vendor-
provided software (AW volume share 4.5 for PET-CT; GE Healthcare,
Waukesha, WI, USA). Each residual peritoneal lesion that matched with
the above-mentioned criteria was considered. The MTV was deﬁned as
the volume where SUV was more than 42% of SUVmax. TLG was de-
rived from the multiplication of MTV and SUVmean of the MTV, deﬁ-
nitively, as the product of SUVavg multiplied by the number of voxels.
On a patient basis, we determined the sum of all MTVs and the cu-
mulative TLG as per tumour burden.
For the volumetric analysis, 16 studies were examined twice by the
same reader (intraobserver reproducibility) and were interpreted by
two diﬀerent readers (interobserver reproducibility).
The patients were categorized into two groups according to
SUVmax, MTV and TLG cut-oﬀ points determined by ROC analysis. The
Table 1
Patient characteristics.
Number 31
Age at diagnosis, years, median (range) 62 (35–79)
Histology
Serous (%) 30 (97)
Endometrioid (%) 0
Clear Cell (%) 0
Mixed Type; neuroedocrine (%) 1 (3)
CA-125, UI/ml, median (range) 80 (12–420)
FIGOa stage
I(%) 0
II(%) 3 (10)
III(%) 28 (90)
IV(%) 0
Tumor Grade
1 (%) 1 (3)
2 (%) 3 (10)
3(%) 24 (77)
Unknown (%) 3 (10)
Apparent residual lesion after surgery
Yes (%) 26 (84)
No (%) 5 (16)
Chemotherapy (6 cycles)
Platinum-based combination fulﬁlled (%) 17 (55)
Platinum-based combination incomplete (%) 14 (45)
No (%) 0
Final patient status
No evidence disease (%) 18 (58)
Alive with disease (%) 7 (22)
Death (%) 4 (13)
Unknown (%) 2 (7)
a FIGO; International Federation of Gynecology and Obstretics.
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performance status and the status of disease were followed up
20 ± 12 months thereafter.
The evaluation was carried out using clinical and haematological
parameters during scheduled or unscheduled visits, on the basis of di-
agnostic imaging (i.e. CT) results (if any) as well as by phone interview.
Main events such as re-intervention, evidence of newly discovered
distant metastases (not peritoneal; as per progression) or death con-
stituted surrogate end-points. PET/CT results were then correlated to
the disease outcome (overall survival; OS). OS was deﬁned as the time
from PET/CT until disease-related death or the time of the last censor.
Chemotherapy resistance was deﬁned as a progression or event that
occurred during the 6 months after completion of a platinum-based
regimen.
Continuous data are expressed as mean ± 1 SD and median.
Comparisons between the mean values were performed with an un-
paired Student’s t-test (two-tailed probability). Intraobserver and in-
terobserver reproducibility for computing MTV and TLG was assessed
by the repeatability coeﬃcient, which is twice the SD of diﬀerences
[14]. We may assume that 95% of diﬀerences are less than a repeat-
ability coeﬃcient.
The receiver-operator-curve (ROC) analysis was performed to esti-
mate the optimal cut-oﬀ of SUVmax, MTV and TLG for diﬀerentiating
patients at high risk of main events. The Cox proportional hazard model
was used to assess prognostic variables estimating the hazard ratio (age,
histology, grade, Ca-125 serum levels, metabolic parameters at PET/CT
and the treatment adopted were tested).
The Kaplan-Meier method was used to plot OS. Predeﬁned cut-oﬀ
points for metabolic variables were implemented and curves compared
by log-rank testing. A probability (p) value< 0.05 was considered
statistically signiﬁcant.
3. Results
Records from 110 patients with EOC were evaluated during the
study period. Among them, 31 patients (mean age 61.3 ± 11 yrs) were
eligible and 26 presented a III C FIGO stage. Individual patient data are
reported in Table 1. The surgery conﬁrmed the presence of a peritoneal
carcinomatosis, and the pelvic primary tumour was removed in all
patients. A nodal/peritoneal CRS was performed and 5 of the 31 pa-
tients had no “apparent” residual disease. The tumours were serous
adenocarcinoma, except for one patient who presented an associated
neuroendocrine component. The mean Ca-125 was 122 ± 143 UI/ml.
Fourteen patients (45%) received subsequent chemotherapy up to 4 of 6
cycles, with chemotherapy being clinically unsustainable thereafter.
The PET/CT was reported as positive in all patients (i.e. signiﬁcant
uptake, visually detectable and higher than 2.5). Global median
SUVmax was 7.6 (range 3–21), median summed MTV was 35.2 cm3
(range 11–368) and median cumulative TLG was 419.4 g (range
182–1097). Volumetric measurements have been recently introduced,
and their practical implementation may result in a lack of reproduci-
bility due to both operator experience and software weakness.
Accordingly, for this analysis, the intraobserver and interobserver re-
producibility was assessed, and the values of the repeatability coeﬃ-
cient are listed in Table 3. On the basis of the above-mentioned as-
sumption, the reproducibility appears to be good for both MTV and
TLG.
The ROC curve analysis recognising cut-oﬀ values of SUVmax, MTV
and TLG for OS are showed in Fig. 1. The AUC for SUVmax was 0.620
and the cut-oﬀ value was 6.53. The AUC for MTV and TLG was 0.691
and 0.673, respectively, whereas MTV and TLG cut-oﬀ values were 44.7
and 317.2, respectively.
Five of 31 patients (16%) underwent second-look re-intervention,
whereas two of 31 (6%) showed newly discovered distant metastases
(one brain, another liver) and four of 31 (13%) died. The second-look
re-intervention conﬁrmed EOC histology (Fig. 2).
The median follow-up was 22 months (range 8–43 months). Among
the parameters tested in a Cox proportional hazard analysis, only an
association between MTV and OS was observed. A better outcome was
associated with higher values of MTV, which signiﬁcantly contributed
to the prediction of time of survival (p = 0.023, HR 0.025, 95% CI
0.001–0.603). The Kaplan-Meier survival analysis for SUVmax did not
show a signiﬁcant diﬀerence in OS (p = 0.48; HR, 0.6, log-rank test).
The survival analysis for MTV showed signiﬁcantly higher OS in pa-
tients presenting a greater tumour burden as compared to those pre-
senting lesser (p = 0.01; HR, 4.8, log-rank test; 26 vs. 14 months),
whereas TLG exhibited a similar trend, though not signiﬁcant, for dis-
criminating among patients (p = 0.06; HR, 3.2, log-rank test) (Fig. 3).
Additionally, the group of patients (n 5) with no apparent residual
disease at surgery presented MTV values below the cut-oﬀ (29 cm3) and
poor outcome. Nine (64%) patients among those who did not ﬁnish
chemotherapy showed MTV values below the cut-oﬀ.
Table 2
Overall timeline of surgery, PET/CT and chemotherapy.
Wks; weeks, aCRS; cytoreductive surgery, bPET/CT; positron emission tomography/computed tomography, cCHTx; chemotherapy. Cross-talk between solid bars is related to the het-
erogeneous patients’ timing.
Table 3
Intraobserver and interobserver reproducibility for MTV and TLG measurements by [F-
18]PET/CT.
MTVa TLGb
Intraobserver RCc 0.167 0.194
Interobserver RC 0.316 0.414
a MTV; Metabolic tumour volume (cm3).
b TLG; total lesion glycolysis (g).
c RC; repeatability coeﬃcient for reproducibility.
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We were able to exclude chemoresistance, because among the pa-
tients who reached the end-point, seven of 11 (64%) developed an
event beyond the sixth month (settled point).
4. Discussion
Cytoreductive surgery followed by platinum-based systemic che-
motherapy results in a complete response for up to 80% of patients with
advanced ovarian epithelial carcinoma. However, only 30% of patients
survive for at least 5 years because of relapse/residuals, post-surgery
signiﬁcant tumour burden or unsuccessful therapy. We investigated the
relationship between functional tumour parameters by PET/CT and
clinical outcome in patients with peritoneal carcinomatosis from EOC
which was intercepted after the cytoreductive surgery, and for whom
chemotherapy was planned. In this study, the sum of MTV computed
from each identiﬁable abdominal lesion rather than indirectly thre-
sholded parameters, such as the SUVmax and the cumulative TLG, was
predictive of survival. Aside from chemo-resistance, the higher the
summed MTV, the better the response to additional therapy will be in
this type of setting.
Some authors [15–17] have already described various [18F] FDG
PET/CT parameters in diﬀerent solid tumours as emerging indicators of
metabolic activity. In particular, SUVmax, MTV and TLG have been
recently used as prognostic variables in EOC patients before surgery
[18–21]. Alternatively, the potential prognostic role of the functional
characterization by PET/CT in EOC has been reported in post-treatment
Fig. 1. ROC curve analysis establishing the cut oﬀ value of global SUVmax, summed MTV and cumulative TLG for predicting OS. The cut oﬀ value of SUVmax (a), MTV (b) and TLG (c)
for stratifying patients was 6.53, 44.7 (cm3) and 317.2 (g), respectively.
Fig. 2. Surface rendering image of patient with
peritoneal carcinomatosis showing remarkable tu-
mour burden (summed MTV: 45 cm3). The ﬁndings
were conﬁrmed at second-look histology.
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settings, following soon after the initial therapy [22–26] as well as for
the deﬁnitive therapy assessment [9,27–32]. To our knowledge this is
the ﬁrst study that shows the prognostic value of functional parameters
by PET/CT in patients with peritoneal carcinomatosis from EOC shortly
after surgery and while awaiting chemotherapy.
Among these functional indicators, the SUV represents a validated
measurement of the body-weight corrected metabolic activity which
does not take into account the representative tumour volume, whereas
the MTV and TLG evaluate tumour-energetic turnover throughout the
volume of the lesion above a minimum threshold designed to exclude
the background activity. Accordingly, volume-based parameters may
reﬂect more accurately the metabolic burden of an active tumour than
the hypermetabolic single-pixel-based SUV would.
In our setting, only the summed MTV, which was calculated con-
sidering the abdominal tumour residuals to surgery, was a statistically
signiﬁcant prognostic factor of survival. It is noteworthy that the pa-
tients presenting higher values of MTV showed a prolonged survival
compared to those having lesser values, indicating that the higher the
tumour burden the better the response to subsequent chemotherapy.
These data appear to be in contrast with previous and recent ﬁnd-
ings [18–21]. In fact, Chung et al. reported [20] that a poor outcome
was associated with higher values for both the MTV and the TLG in 55
patients with EOC and Lee et al. [19] described that, in addition to the
tumour stage, TLG is an independent prognostic factor for disease
progression in a similar setting. However, in these studies, unlike ours,
the PET/CT was performed before the cytoreductive surgery when the
whole tumour load was still on-site, which could have inﬂuenced the
results. In addition, other previous studies have indicated prolonged
survival after the surgery once the all evidence of macroscopic disease
seemed to be eliminated. These last data mainly focused on the primary
tumour (and less so on the peritoneum) and did not consider the con-
tribution of the PET/CT diagnostic [33,34]. More recently, some au-
thors also compared the prognostic value of data from PET/CT with
those obtained by contrast-enhanced CT (CECT) [24–26]. Rubini et al.
showed that PET/CT had a diagnostic accuracy of 88%, higher than that
of CECT, for detecting peritoneal carcinomatosis. However, these stu-
dies were carried out for testing the value of PET/CT to detect un-
diagnosed/unknown peritoneal carcinomatosis or for predicting out-
come/post-relapse survival in patients complying with recurrent EOC
distant from the initial treatment [24,25], while our patients had sus-
pected peritoneal carcinomatosis and did not have a local recurrence.
Moreover, there is evidence that volumetric assessment by PET/CT has
a powerful prognostic value in EOC also after surgery [22,23,30].
Nevertheless, Chu et al. focused on the incremental value of PET/CT in
improving prognostic accuracy, particularly in the subset of patients
with negative CA-125 [22]. Recently, Vallius et al. evaluated whether
PET/CT is useful for identifying unresponsive patients to neoadjuvant
CHTx. Unlike us, they did not use volumetric parameters, but only
SUVmax, and concluded that PET/CT can identify unresponsive pa-
tients who would beneﬁt from second-line CHTx instead of debulking,
thus endorsing the need for a substantial metabolic response [23].
Yamamoto et al. [30] reported that volumetric parameters MTV and
TLG could serve as potential surrogate biomarkers for recurrence in
patients who undergo both CRS and CHTx, identifying patients at high
risk of recurrence. This group of patients diﬀers from ours because the
impact on ﬁndings of CHTx cannot be ruled out. Our patients con-
stituted a particular setting compared to those of the latter studies. They
had undergone cytoreductive surgery, since peritoneal carcinomatosis
was suspected (then conﬁrmed by surgery), they received at least a
complete surgical pelvic intervention (on the primary tumour) and they
had a PET/CT study for restaging before implementing a platinum-
based therapy. The chemotherapy was timed or delayed according to
their GOG score and the referring physicians.
Mayoral et al. and Caobelli et al. [31,32] also reported on the role of
PET/CT parameters as useful prognostic predictors of outcome, but in
patients with recurrent EOC [31] distant from the ﬁrst remission, or for
restaging, using only the SUV [32].
Although our ﬁndings appear unusual it is conceivable that patients
presenting with metabolically active disease would respond better to
chemotherapy along with the log-kill hypothesis. In fact, chemother-
apeutic agents kill a constant fraction of cells, rather than a speciﬁc
number of cells, increasing the likelihood that repeated cycles of che-
motherapy will reduce the number of viable tumour cells toward zero,
after the initial surgical reduction of tumour volume [35]. Therefore,
the higher the MTV, the higher is the absolute number of cells killed
every cycle (translating to tumour-shrinkage), and hence, the better is
the response to additional therapy.
Moreover, most of the patients with lower MTV did not complete
chemotherapy, which may partially substantiate their poor outcome.
For them, at least, alternative approaches would have been envisaged.
Metabolic assessment after surgery and before chemotherapy might
be helpful for stratifying patients with advanced EOC who are at high
risk for not responding to treatment, and for those who may beneﬁciate
from a complete aggressive therapeutic regimen albeit the considerable
tumour burden. Accordingly, our ﬁndings support the idea that the
volume-based evaluation in EOC peritoneal carcinomatosis, after the
debulking, addresses the question of which patients warrant full-re-
gimen/alternative chemotherapy (i.e. biologic drugs or intra-perito-
neal) and which patients warrant a less aggressive approach sparing
some treatment-related co-morbidities and costs. Our data also suggest
that the PET/CT could be useful for an ad-interim restaging [36].
The lack of a gold standard against which to compare positive PET/
CT ﬁndings could be disputed. Most of the patients had elevated Ca-125
levels. Those who experienced main events mostly underwent re-in-
tervention with a histologically proven relapse.
We deﬁned the chemoresistance as a progression/event that
Fig. 3. Kaplan-Meier survival graphs indicate a signiﬁcant diﬀerence in OS between the group of patients categorized by MTV. a Kaplan-Meier graph of global SUVmax and OS showing
SUVmax above (dotted line) and below (solid line) the cut oﬀ of 6.53. b Kaplan-Meier graph of summed MTV and OS with MTV above (dotted line) and below (solid line) the cut oﬀ of
44.7 cm3. High MTV is coupled with prolonged survival (p = 0.01, log-rank test). c Kaplan-Meier graph of cumulative TLG and OS with TLG above (dotted line) and below (solid line) the
cut oﬀ of 317.2 (g).
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occurred during the 6 months following the completion of a platinum-
based regimen. Accordingly, because most of the patients who reached
the end-point developed a main event signiﬁcantly later (more than six
months after completion of treatment), we deﬁnitively ruled out che-
moresistance as a factor inﬂuencing the outcome.
From a technical point of view, it could be argued that summed
MTV constituted a powerful indicator, whereas TLG, which is MTV-
based, did not. However, similar to SUVmax, which considers a single
hypermetabolic pixel, TLG contains the SUVavg as a straight non-
thresholded parameter. It could be postulated that parameters without
a threshold may result in a less accurate lesion/background dis-
crimination in such a particular abdominal environment. Discrepancy
on the value of TLG has been already reported in this setting [19,31].
Nevertheless, TLG results showed a trend similar to that of MTV, though
not signiﬁcant, and somewhat auto-referential to our Institution.
Assessment of disease by [18F] FDG PET/CT early after surgery may
eﬀect a number of false positive results, especially when an extensive
abdominal surgery has been carried out. However, our patients un-
derwent PET/CT 4 ± 1 months after surgery, when the confounding
variables (i.e. inﬂammation) may be mainly ruled out. Although there
is a lack of standardized criteria, the role of the volumetric analysis by
[18F]FDG PET/CT in haematological [37] and solid tumours [38], such
as in EOC, is promising.
5. Conclusion
The quantitative assessment by MTV rather than SUVmax and TLG
on [18F]FDG PET/CT may be helpful for patients presenting peritoneal
carcinomatosis from EOC after debulking and before chemotherapy,
when a proper survival stratiﬁcation is warranted. The role of the vo-
lumetric analysis by [18F] FDG PET/CT in solid tumours such as EOC is
emerging, and justiﬁes its use in larger settings.
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